Dana-Farber Cancer Institute is running a clinical trial to test drugs called Ibrutinib, Fludarabine, Cyclophosphamide and Rituximab to treat chronic lymphocytic leukemia. This research study is evaluating a new drug called ibrutinib in combination with the standard drugs fludarabine, cyclophosphamide, and rituximab (FCR) as a possible treatment for Chronic Lymphocytic Leukemia (CLL).
The drugs are Ibrutinib, Fludarabine, Cyclophosphamide and Rituximab.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||85 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase II Study of Ibrutinib in Combination With Fludarabine, Cyclophosphamide, and Rituximab (iFCR) in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia|
|Actual Study Start Date :||October 2014|
|Estimated Primary Completion Date :||April 2018|
|Estimated Study Completion Date :||April 2021|
For enrollment please visit www.clinicaltrials.gov.